8-K: Quanterix Q3 2025 Revenue Meets Expectations, Synergies on Track

Quanterix Corporation announced third quarter 2025 financial results, meeting revenue expectations and progressing with Akoya integration to achieve cash flow break-even in 2026.

Summary

• Third quarter 2025 revenue reached $40.2 million, marking a 12.3% increase compared to $35.8 million in the prior year.
• GAAP gross margin for Q3 2025 was 42.8%, a decrease from 56.3% in Q3 2024, while adjusted gross margin (non-GAAP) was 45.9%, down from 50.7% in the prior year.
• Adjusted EBITDA (non-GAAP) loss widened to $11.9 million, compared to a loss of $5.5 million in Q3 2024, primarily due to higher acquisition and restructuring charges.
• The company ended the third quarter with $138.1 million in cash, cash equivalents, marketable securities, and restricted cash.
• Adjusted cash usage for Q3 2025 was $16.1 million, with expectations for it to decline in Q4 2025 due to improved working capital and full effect of cost synergies.
• Key integration activities from the Akoya transaction have captured $67 million of cost synergies and savings, with a target of $85 million in annualized synergies.
• Quanterix reiterated its full-year 2025 revenue guidance of $130 to $135 million, including approximately two quarters of Akoya's performance, and a pro forma revenue of $165 to $170 million.
• The company expects to exit 2025 with approximately $120 million in cash and anticipates achieving cash flow break-even performance in 2026.

Sentiment

Score: 6

Explanation: While the company reported increased net losses and a wider adjusted EBITDA loss due to acquisition and restructuring costs, it met revenue expectations and is making significant progress on Akoya integration and synergy realization. The reiterated full-year guidance and expectation of cash flow breakeven in 2026 provide a positive future outlook, but current financial performance shows challenges.

Positives

• Achieved Q3 2025 revenue of $40.2 million, meeting expectations despite challenging market conditions and representing a 12.3% increase year-over-year.
• Successfully executed key integration activities for the Akoya acquisition, capturing $67 million of cost synergies and savings towards an annualized target of $85 million.
• Remains firmly on track to achieve cash flow break-even performance in 2026.
• The Alzheimer's diagnostics business is accelerating, supported by a positive Medicare pricing recommendation and expanding partnerships across Asia (All-Eight, Union Clinical Laboratory, NSW Health Pathology).
• Launched eight new Simoa assays through the first nine months of 2025, expanding the product portfolio.
• Delivered multiple spatial and immuno-oncology presentations at the 40th annual Society for Immunotherapy of Cancer (SITC), demonstrating growing adoption of high-plex spatial proteomics and AI-driven analysis platforms.
• Introduced a new Metabolism Spike-in Module for the PhenoCycler-Fusion and PhenoCode Discovery IO60 Human Protein Panel.

Negatives

• GAAP gross margin decreased to 42.8% in Q3 2025 from 56.3% in Q3 2024.
• Adjusted gross margin (non-GAAP) decreased to 45.9% in Q3 2025 from 50.7% in Q3 2024.
• Adjusted EBITDA (non-GAAP) loss significantly widened to $11.9 million in Q3 2025 from $5.5 million in Q3 2024, primarily due to higher acquisition and restructuring charges.
• Net loss increased to $(33.5) million in Q3 2025 from $(8.4) million in Q3 2024.
• Total current assets decreased from $363.6 million at December 31, 2024, to $233.3 million at September 30, 2025.
• Net cash used in operating activities for the nine months ended September 30, 2025, was $(60.8) million, an increase from $(30.9) million for the same period in 2024.

Risks

• Risks related to the impact of recent U.S. government policies, including reductions in federal research funding and increased tariffs.
• Risks that the expected benefits of cost reduction actions may not be realized.
• Risks associated with the anticipated timing for launch of, and features of, Quanterix’s next-generation instrument, Simoa One.
• Risks that Quanterix may fail to realize the anticipated benefits and synergies of its recent acquisitions of Emission, Inc. and Akoya Biosciences Inc.
• Risk that integrating Quanterix’s business with that of Akoya could be more difficult, costly or time-consuming than expected.
• Risks that Quanterix’s estimates regarding expenses, future revenues, capital requirements, and needs for additional financing could be incorrect.
• Risks related to the restatement of Quanterix’s consolidated financial statements, including risks of increased costs and the increased possibility of legal proceedings and regulatory inquiries, sanctions, or investigation.
• Risks related to Quanterix’s ability to maintain effective internal control over financial reporting and disclosure controls and procedures, including its ability to remediate existing material weaknesses in its internal control over financial reporting and the timing of any such remediation.
• Risks related to defects or other quality issues in Quanterix’s products that could lead to unforeseen costs, product recalls, adverse regulatory actions, negative publicity and litigation.
• Risks related to Quanterix’s ability to retain and expand its customer base and achieve sufficient market acceptance of its products.

Future Outlook

Quanterix reiterates its 2025 full-year revenue guidance of $130 to $135 million, with a pro forma revenue of $165 to $170 million assuming full-year combination with Akoya. GAAP and adjusted gross margin are expected to be in the range of 45% to 47%. The company anticipates 2025 adjusted cash usage to be approximately $34 to $38 million and expects to exit 2025 with approximately $120 million in cash. Quanterix projects achieving cash flow breakeven performance in 2026.

Management Comments

• "During the third quarter, we delivered on our revenue expectations despite challenging market conditions." Masoud Toloue, Chief Executive Officer.
• "Equally important, we achieved key integration milestones from our Akoya transaction keeping us firmly on track to realize $85 million in annualized synergies and reach cash flow break-even in 2026." Masoud Toloue, Chief Executive Officer.
• "Together, we have built a stronger, more scalable company with the foundation to drive sustained growth, profitability, and cash flow in the years ahead." Masoud Toloue, Chief Executive Officer.
• "Our Alzheimer's diagnostics business also continues to accelerate. With a positive Medicare pricing recommendation and expanding partnerships across Asia, we are advancing toward a future where blood-based testing for neurodegenerative disease becomes standard clinical practice and Quanterix is at the center of that transformation." Masoud Toloue, Chief Executive Officer.

Industry Context

Quanterix operates in the rapidly evolving fields of ultra-sensitive biomarker detection and spatial biology. The integration of Akoya Biosciences positions the company to offer a more comprehensive platform connecting biology across blood and tissue, aligning with the broader trend towards precision medicine. The acceleration of its Alzheimer's diagnostics business, supported by a positive Medicare pricing recommendation and international partnerships, indicates a strong position in the growing market for neurodegenerative disease diagnostics, potentially setting a new standard for blood-based testing.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through strategic acquisitions and synergy realization, but current losses and cash usage may cause short-term concern. The reiterated guidance and path to profitability in 2026 offer a clear roadmap.
• Employees: Integration activities involved combining sales organizations, consolidating facilities, and eliminating redundant G&A, implying workforce adjustments and potential impact on employees from the restructuring plan announced in 2025.
• Customers: Benefit from a combined, broader portfolio of products and integrated platforms connecting blood and tissue biology, enhancing research and diagnostic capabilities.
• Creditors: The company ended Q3 with $138.1 million in cash and expects $120 million by year-end, indicating sufficient liquidity in the near term, with no debt mentioned.

Next Steps

• Continue integration activities for Akoya Biosciences, including physical consolidation, commercial team integration, G&A elimination, manufacturing team integration, lab services combination, and full systems and financial integration.
• Realize the remaining $18 million of annualized cost synergies to reach the $85 million target.
• Work towards achieving cash flow break-even performance in 2026.
• Advance the Alzheimer's diagnostics business, expanding partnerships and promoting blood-based testing.
• Launch the next-generation instrument, Simoa One.

Key Dates

Recommendation

While Quanterix reported increased losses and cash usage in Q3 2025, these are largely attributed to acquisition and restructuring costs related to the Akoya integration. The company met revenue expectations and is on track to achieve significant annualized synergies and cash flow breakeven in 2026. The strategic direction, particularly in Alzheimer's diagnostics and spatial biology, is promising. However, the current financial performance indicates ongoing challenges. A 'hold' recommendation is appropriate as investors should monitor the execution of synergy realization and the path to profitability in 2026 before making further investment decisions, balancing the long-term strategic potential against short-term financial headwinds.

Keywords

Quanterix, QTRX, financial results, biomarker detection, Simoa, Akoya Biosciences, spatial biology, Alzheimer's diagnostics, neurodegenerative disease, precision medicine, biotech, life sciences, diagnostics, proteomics, immuno-oncology, synergies, cash flow breakeven